Adherence and patient'experiences with the use of erlotinib in NSCLC treatment: the influence on plasma concentration and the exploration of factors affecting the use in daily practice.
Phase of Trial: Phase IV
Latest Information Update: 23 May 2013
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms Caper
- 24 May 2010 Planned end date changed from 1 Jul 2010 to 1 Dec 2010 Netherlands Trials Register record.
- 18 May 2010 Status changed from planning to recruiting as reported by Netherlands Trials Register record.
- 16 Jun 2009 New trial record